Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNEX-3: iclepertin for cognitive impairment in schizophrenia
2020-003726-23Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Iclepertin once daily with Placebo once daily (2 arms). Primary endpoint: Change in overall composite MCCB T-score at 26 weeks. Started Feb 2021; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2020-003726-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003726-23.